Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer
Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer
复制标题
DOI：
10.1002/ijc.10801
复制
发表时间：
2003-01-01
影响因子：
6.4
通讯作者：
Hinoda, Y
中科院分区：
文献类型：
--
作者：
Hamanaka, Y;Suehiro, Y;Hinoda, Y
MUCI在体内具有免疫原性，并且已经在癌症患者中检测到针对MUCI的体液和细胞免疫应答。我们的研究探讨了循环抗MUCI抗体与胰腺癌临床病理参数或患者生存期的相关性。对36例胰腺浸润性导管癌患者的血清标本进行抗MUCI IgG或IgM抗体的酶免疫测定。抗MUCI IgG抗体的血清水平与存活时间显著相关（p = 0.0004），而抗MUCI IgM和抗Gala（1，3）Gal IgG抗体（后者被称为与MUCI交叉反应的天然抗体）的血清水平均未显示出给定的趋势。一些具有较高抗体滴度的患者血清显示与培养的胰腺癌细胞的MUCI转染子反应，但不与MUCI阴性亲本细胞反应。根据血清抗MUCI抗体水平将样本初步分为2组时，光密度≥ 0.3组患者的生存时间明显长于光密度
MUCI is immunogenic in vivo and humoral and cellular immune responses against MUCI have been detected in cancer patients. Our study explored the association of circulating anti-MUCI antibodies with clinicopathological parameters or patients' survival of pancreatic cancer. Serum specimens from 36 patients with invasive ductal carcinoma of the pancreas were subjected to enzyme immunoassay for anti-MUCI IgG or IgM antibodies. Serum levels of anti-MUCI IgG antibodies were significantly correlated with survival time (p = 0.0004), whereas neither those of anti-MUCI IgM nor anti-Gala(1,3)Gal IgG antibodies, the latter known as natural antibodies cross-reactive with MUCI, showed a given tendency. Some patients' sera with the higher antibody titer showed the reactivity with MUCI-transfectants of cultured pancreatic cancer cells, but not with MUCI-negative parental cells. When the samples were tentatively divided into 2 groups by the serum level of anti-MUCI antibodies, the survival of patients was significantly longer in the group with optical density greater than or equal to0.3 than in that with optical density